Intercept(Biotechnology) Overview

  • Founded
  • 2002
Founded
  • Status
  • Public
  • Employees
  • 498
Employees
  • Stock Symbol
  • ICPT
Stock Symbol
  • Share Price
  • $16.56
  • (As of Tuesday Closing)

Intercept(Biotechnology) General Information

Description

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 10 Hudson Yards
  • 37th Floor
  • New York, NY 10001
  • United States
+1 (646) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Intercept(Biotechnology) Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.56 $17.76 $11.60 - $38.94 $525M 29.5M 876K -$3.27

Intercept(Biotechnology) Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 598,735 888,981 3,875,512 2,867,014
Revenue 354,332 312,690 252,002 179,804
EBITDA (52,650) (223,708) (299,874) (274,137)
Net Income (107,293) (274,880) (344,681) (309,242)
Total Assets 523,074 580,489 754,886 509,167
Total Debt 539,927 575,514 547,756 371,250
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Intercept(Biotechnology) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Intercept(Biotechnology)‘s full profile, request access.

Request a free trial

Intercept(Biotechnology) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Intercept(Biotechnology)‘s full profile, request access.

Request a free trial

Intercept(Biotechnology) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chr
Drug Discovery
New York, NY
498 As of 2020
00000
000000 - 000 00000

0000000

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Copenhagen, Denmark
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000000

mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
San Diego, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Intercept(Biotechnology) Competitors (65)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Galecto Formerly VC-backed Copenhagen, Denmark 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
0000000000 0000000 Venture Capital-Backed Mont-Saint-Guibert, Belgium 00 00000 0000000000 0
00000000 Formerly VC-backed Needham, MA 00 00000 000000 - 000 00000
000000 000000 Corporation London, United Kingdom 00 00000 000000000 00000
You’re viewing 5 of 65 competitors. Get the full list »

Intercept(Biotechnology) Patents

Intercept(Biotechnology) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200316092-A1 Methods of diagnosis and treatment of liver diseases using obeticholic acid Pending 26-Mar-2019 0000000000
EP-3876944-A1 Methods of using obeticholic acid Pending 08-Nov-2018 0000000000
AU-2019374797-A1 Methods of using obeticholic acid Pending 08-Nov-2018 0000000000
CA-3117966-A1 Methods of using obeticholic acid Pending 08-Nov-2018 0000000000
US-20200147108-A1 Methods of using obeticholic acid Abandoned 08-Nov-2018 A61K31/575
To view Intercept(Biotechnology)’s complete patent history, request access »

Intercept(Biotechnology) Executive Team (23)

Name Title Board Seat Contact Info
Jerome Durso Chief Executive Officer & Board Member
Michelle Berrey MD Chief Medical Officer & President of Research & Development
Rocco Venezia Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Linda Richardson Executive Vice President & Executive
Roberto Pellicciari Scientific Founder & Medicinal Chemist
You’re viewing 5 of 23 executive team members. Get the full list »

Intercept(Biotechnology) Board Members (17)

Name Representing Role Since
Dagmar Rosa-Bjorkeson Self Board Member 000 0000
Daniel Bradbury Self Board Member 000 0000
Gino Santini Intercept(Biotechnology) Board Member 000 0000
Glenn Sblendorio Self Board Member 000 0000
Jerome Durso Intercept(Biotechnology) Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Intercept(Biotechnology) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intercept(Biotechnology) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Intercept(Biotechnology)‘s full profile, request access.

Request a free trial